Glucagon antagonism as a potential therapeutic target in type 2 diabetes

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Glucagon antagonism as a potential therapeutic target in type 2 diabetes. / Bagger, J I; Knop, F K; Holst, Jens Juul; Vilsbøll, T.

In: Diabetes, Obesity and Metabolism, Vol. 13, No. 11, 11.2011, p. 965-971.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Bagger, JI, Knop, FK, Holst, JJ & Vilsbøll, T 2011, 'Glucagon antagonism as a potential therapeutic target in type 2 diabetes', Diabetes, Obesity and Metabolism, vol. 13, no. 11, pp. 965-971. https://doi.org/10.1111/j.1463-1326.2011.01427.x

APA

Bagger, J. I., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2011). Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes, Obesity and Metabolism, 13(11), 965-971. https://doi.org/10.1111/j.1463-1326.2011.01427.x

Vancouver

Bagger JI, Knop FK, Holst JJ, Vilsbøll T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes, Obesity and Metabolism. 2011 Nov;13(11):965-971. https://doi.org/10.1111/j.1463-1326.2011.01427.x

Author

Bagger, J I ; Knop, F K ; Holst, Jens Juul ; Vilsbøll, T. / Glucagon antagonism as a potential therapeutic target in type 2 diabetes. In: Diabetes, Obesity and Metabolism. 2011 ; Vol. 13, No. 11. pp. 965-971.

Bibtex

@article{8f1d8b4987ab4c8fb30f4282ac88276e,
title = "Glucagon antagonism as a potential therapeutic target in type 2 diabetes",
abstract = "Glucagon is a hormone secreted from the alpha cells of the pancreatic islets. Through its effect on hepatic glucose production (HGP), glucagon plays a central role in the regulation of glucose homeostasis. In patients with type 2 diabetes mellitus (T2DM), abnormal regulation of glucagon secretion has been implicated in the development of fasting and postprandial hyperglycaemia. Therefore, new therapeutic agents based on antagonizing glucagon action, and hence blockade of glucagon-induced HGP, could be effective in lowering both fasting and postprandial hyperglycaemia in patients with T2DM. This review focuses on the mechanism of action, safety and efficacy of glucagon antagonists in the treatment of T2DM and discusses the challenges associated with this new potential antidiabetic treatment modality.",
keywords = "Biphenyl Compounds, Diabetes Mellitus, Type 2, Fasting, Glucagon, Glucagon-Secreting Cells, Humans, Hyperglycemia, Hypoglycemic Agents, Liver, Receptors, Glucagon, Signal Transduction",
author = "Bagger, {J I} and Knop, {F K} and Holst, {Jens Juul} and T Vilsb{\o}ll",
note = "{\textcopyright} 2011 Blackwell Publishing Ltd.",
year = "2011",
month = nov,
doi = "10.1111/j.1463-1326.2011.01427.x",
language = "English",
volume = "13",
pages = "965--971",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "11",

}

RIS

TY - JOUR

T1 - Glucagon antagonism as a potential therapeutic target in type 2 diabetes

AU - Bagger, J I

AU - Knop, F K

AU - Holst, Jens Juul

AU - Vilsbøll, T

N1 - © 2011 Blackwell Publishing Ltd.

PY - 2011/11

Y1 - 2011/11

N2 - Glucagon is a hormone secreted from the alpha cells of the pancreatic islets. Through its effect on hepatic glucose production (HGP), glucagon plays a central role in the regulation of glucose homeostasis. In patients with type 2 diabetes mellitus (T2DM), abnormal regulation of glucagon secretion has been implicated in the development of fasting and postprandial hyperglycaemia. Therefore, new therapeutic agents based on antagonizing glucagon action, and hence blockade of glucagon-induced HGP, could be effective in lowering both fasting and postprandial hyperglycaemia in patients with T2DM. This review focuses on the mechanism of action, safety and efficacy of glucagon antagonists in the treatment of T2DM and discusses the challenges associated with this new potential antidiabetic treatment modality.

AB - Glucagon is a hormone secreted from the alpha cells of the pancreatic islets. Through its effect on hepatic glucose production (HGP), glucagon plays a central role in the regulation of glucose homeostasis. In patients with type 2 diabetes mellitus (T2DM), abnormal regulation of glucagon secretion has been implicated in the development of fasting and postprandial hyperglycaemia. Therefore, new therapeutic agents based on antagonizing glucagon action, and hence blockade of glucagon-induced HGP, could be effective in lowering both fasting and postprandial hyperglycaemia in patients with T2DM. This review focuses on the mechanism of action, safety and efficacy of glucagon antagonists in the treatment of T2DM and discusses the challenges associated with this new potential antidiabetic treatment modality.

KW - Biphenyl Compounds

KW - Diabetes Mellitus, Type 2

KW - Fasting

KW - Glucagon

KW - Glucagon-Secreting Cells

KW - Humans

KW - Hyperglycemia

KW - Hypoglycemic Agents

KW - Liver

KW - Receptors, Glucagon

KW - Signal Transduction

U2 - 10.1111/j.1463-1326.2011.01427.x

DO - 10.1111/j.1463-1326.2011.01427.x

M3 - Journal article

C2 - 21615669

VL - 13

SP - 965

EP - 971

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 11

ER -

ID: 38531952